- Recursion Pharmaceuticals Inc (NASDAQ:RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC:BAYRY).
- The expanded collaboration will include Recursion’s inferential search capabilities based on its growing maps of human cellular biology.
- Recursion and Bayer may now work on more than a dozen programs in a total of relevance to fibrotic disease.
- All projects will remain subject to the previously agreed upon economics, where each potential program could generate more than $100 million in commercial milestone payments plus royalties on future sales.
- In the expanded collaboration, the Company will leverage the Recursion Map to explore hundreds of billions of biological relationships that span whole-genome genetic perturbations, hundreds of soluble factors, and hundreds of thousands of pharmacological perturbations.
- Price Action: RXRX shares are up 5.47% at $18.69 during the market session on the last check Monday.
Outset Medical Q4 EPS $(0.77), Inline, Sales $28.20M Beat $26.42M Estimate
Outset Medical (NASDAQ:OM) reported quarterly losses of $(0.77) per share which met the analyst consensus estimate. This is a 2.67 percent decrease over losses of $(0.75) per share from the same period last year. The
